Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Akari Therapeutics plc (AKTX) ADR each Representing 100 Shares

Sell:$2.08 Buy:$2.10 Change: $0.03 (1.42%)
NASDAQ:1.44%
Market closed |  Prices as at close on 8 July 2020 | Switch to live prices |
Sell:$2.08
Buy:$2.10
Change: $0.03 (1.42%)
Deal now Deal for just £11.95 per trade in a Fund and Share Account
Market closed |  Prices as at close on 8 July 2020 | Switch to live prices |
Sell:$2.08
Buy:$2.10
Change: $0.03 (1.42%)
Market closed |  Prices as at close on 8 July 2020 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Fund and Share Account
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Akari Therapeutics, Plc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5), including paroxysmal nocturnal hemoglobinuria, Guillain Barre syndrome and atypical Hemolytic Uremic Syndrome. The Company’s lead product candidate, nomacopan inhibits both terminal complement activation and leukotriene B4, or LTB4. It inhibits terminal complement activation by tightly binding to C5 and preventing its cleavage and activation by complement.

Contact details

Address:
24 W 40th St Fl 8
NEW YORK
10018-1028
United States
Telephone:
+1 (646) 3500702
Website:
akaritx.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
AKTX
ISIN:
US00972G1085
Market cap:
$64.10 million
Shares in issue:
2.87 billion
Sector:
Pharmaceuticals
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Ray Prudo
    Chairman of the Board
  • David Solomon
    Chief Executive Officer
  • Torsten Hombeck
    Chief Financial Officer
  • Clive Richardson
    Chief Operating Officer, Director
  • Nigel Hernandez
    Vice President - Worldwide Regulatory Affairs

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a Fund and Share Account

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.